ODS Gold Sponsors ADA Forsyth Dentech-Asia 2026, Showcases AlignMiracle Direct 3D Printed Clear Aligner

South Korean dental AM specialist ODS (CEO Park Sung-won) participated as a Gold Sponsor at the inaugural ADA Forsyth Dentech-Asia 2026, held May 11-12 at Seoul National University's Siheung Campus Convention Center. The event, co-hosted by the US-based ADA Forsyth Institute (AFI) and Seoul National University, marks the first Asian expansion of the Boston-originated dentech platform. ODS CEO Park Sung-won delivered the opening keynote and operated a booth to promote the company's flagship product, AlignMiracle, the world's first direct 3D printed clear aligner system. ODS is currently conducting US clinical trials for AlignMiracle through an official partnership with AFI, and used the event to deepen collaboration with AFI representatives and expand its global business network with overseas dental institutions and investors.

This event places ODS squarely within the medical-dental vertical's accelerating shift from indirect (model-based) to direct-print aligner workflows. AlignMiracle bypasses traditional multi-step thermoforming by printing the aligner directly in a biocompatible resin, compressing production time and improving fit precision. ODS competes in a space dominated by Align Technology's iTero/Thermoformer ecosystem and a growing cohort of Asian direct-print entrants. The AFI partnership for US clinical trials is strategically critical: FDA 510(k) clearance or CE-MDR certification would create a qualification-based moat (P3 — IP lock-in grind) that differentiates ODS from lower-cost Asian rivals. Dentech-Asia's positioning as the "CES of dentistry" provides a high-visibility platform for ODS to court US and Chinese partners, though the company remains a small player relative to Align's scale.

For ODS, the practical next step is converting its AFI clinical trial into a regulatory filing within 12-18 months. Without a cleared device, the AlignMiracle narrative remains pre-commercial. The company's vertical integration — developing its own printer and proprietary resin — is a structural advantage if it can demonstrate repeatable clinical outcomes at scale. Buyers should watch for published trial data and FDA submission timelines; sponsorship visibility alone does not signal market readiness.